<DOC>
	<DOCNO>NCT00005892</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine effectiveness moderate dose cyclophosphamide radiotherapy term improve survival reduce morbidity follow allogeneic bone marrow transplantation patient myelodysplastic syndrome acute leukemia relate Fanconi 's anemia .</brief_summary>
	<brief_title>Study Allogeneic Bone Marrow Transplantation Following Cyclophosphamide Radiotherapy Patients With Myelodysplastic Syndrome Acute Leukemia Related Fanconi 's Anemia</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients receive cyclophosphamide IV 1-2 hour day -6 -3 total body radiotherapy day -1 . Patients undergo allogeneic bone marrow transplantation day 0 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Diagnosis Fanconi 's anemia family history typical phenotype include : Short stature Hypoplastic radius Skin pigmentation Renal anomaly Chromosomal fragility Evidence Fanconi 's myelodysplastic syndrome Bone marrow dysplasia 3 marrow cell line AND Clonal cytogenetic abnormality demonstrable marrow cell First complete remission follow therapy Fanconi 's acute leukemia allow Must relate histocompatible donor No evidence excessive vitro chromosome fragility typical Fanconi 's anemia Normal CBC bone marrow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>Fanconi 's anemia</keyword>
	<keyword>acute leukemia</keyword>
	<keyword>acute lymphocytic leukemia</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>aplastic anemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>hematologic disorder</keyword>
	<keyword>hematopoietic/lymphoid cancer</keyword>
	<keyword>leukemia</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>oncologic disorder</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>rare disease</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>